TY - JOUR
T1 - Carcinoma Ex Pleomorphic Adenomas
T2 - An Institutional Experience and Literature Review
AU - Tondi-Resta, Isabella
AU - Hobday, Sara B.
AU - Gubbiotti, Maria A.
AU - Jalaly, Jalal B.
AU - Rassekh, Christopher H.
AU - Montone, Kathleen T.
AU - Baloch, Zubair W.
N1 - Funding Information:
We thank the Departments of Pathology and Laboratory Medicine and Otorhinolaryngology for their support in developing this study.
Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Objectives: To provide an institutional experience with cases diagnosed as carcinoma ex pleomorphic adenoma (CXPA), including the cytologic and histologic findings and clinical follow-up, followed by a comparison to the experience documented in the literature. Methods: We identified cases of CXPA diagnosed at our institution from 2011 to 2021 and reviewed the cytologic and histologic diagnoses, as well as the treatment and clinical outcomes. Additionally, a literature review of the English literature was performed on CXPAs from 2011 to 2021. Results: Forty-one cases of CXPA were identified, with the majority subclassified as adenocarcinoma, not otherwise specified. Five tumors underwent cytogenetic studies and five underwent molecular studies. To date, 36 patients are alive, 8 of whom experienced locoregional recurrence or distant metastasis. Conclusions: Our institutional experience was comparable to that reported in the literature. Further studies are required to inquire about the role of molecular profiles of CXPAs in clinical risk assessment.
AB - Objectives: To provide an institutional experience with cases diagnosed as carcinoma ex pleomorphic adenoma (CXPA), including the cytologic and histologic findings and clinical follow-up, followed by a comparison to the experience documented in the literature. Methods: We identified cases of CXPA diagnosed at our institution from 2011 to 2021 and reviewed the cytologic and histologic diagnoses, as well as the treatment and clinical outcomes. Additionally, a literature review of the English literature was performed on CXPAs from 2011 to 2021. Results: Forty-one cases of CXPA were identified, with the majority subclassified as adenocarcinoma, not otherwise specified. Five tumors underwent cytogenetic studies and five underwent molecular studies. To date, 36 patients are alive, 8 of whom experienced locoregional recurrence or distant metastasis. Conclusions: Our institutional experience was comparable to that reported in the literature. Further studies are required to inquire about the role of molecular profiles of CXPAs in clinical risk assessment.
KW - Carcinoma ex pleomorphic adenoma
KW - Pleomorphic adenoma
UR - http://www.scopus.com/inward/record.url?scp=85159257345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159257345&partnerID=8YFLogxK
U2 - 10.1093/ajcp/aqac181
DO - 10.1093/ajcp/aqac181
M3 - Article
C2 - 36921078
AN - SCOPUS:85159257345
SN - 0002-9173
VL - 159
SP - 502
EP - 515
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 5
ER -